The present disclosure relates generally to the field of molecular electronic biosensors, and particularly to the design and use of modified deoxynucleotide triphosphates (dNTPs) to enhance signals produced by molecular electronic sensors.
Molecular electronics generally refers to the use of single molecules or molecular assemblies as components of an electronic circuit. In particular, such a circuit may comprise a sensing circuit in which the single molecules constitute the transducer that interacts with a test solution to produce an electrical signal related to the composition of the test solution. Of concern are applications where a sensor complex comprises a polymerase enzyme to provide the capability to sense properties of DNA and/or RNA molecules in a test solution. In this type of bio-sensor, the polymerase interacts with a DNA or RNA molecule as a template for polymerization of a complementary strand, which the polymerase produces by incorporating dNTPs provided in the test solution, and in so doing modulates the parameters of a molecular circuit to produce electrical signals. For this class of polymerase-based biosensors, one important factor of the performance is dNTP content of the solution.
In spite of the advancements in molecular sensors and the level of sophistication of molecular sensors comprising a polymerase enzyme, the overall signal, and/or signal-to-noise-ratio (SNR) related to nucleotide incorporation events may not be sufficient to distinguish between dNTPs or to detect particular molecular events. Hence, further improvements to these sensors is continuously warranted, including possible modifications to dNTPs that may improve overall signal and/or signal-to-noise-ratio in molecular sensors comprising polymerase enzyme.
In various embodiments of the present disclosure, modified dNTPs, synthesis of modified dNTPs, and use of modified dNTPs in molecular sensors are disclosed. Modified dNTPs in accordance to the present disclosure are shown to improve signaling performance in molecular sensors, including enhancing the overall signal, providing distinguishing signal shape, and/or improving signal-to-noise-ratio related to nucleotide incorporation events in molecular sensors comprising a polymerase enzyme.
In various embodiments, a modified nucleotide (modified dNTP) is disclosed. The modified nucleotide comprises a structure represented by compound [16],
wherein: Nuc is A, T, C, or G; Y is selected from O, S, B or I; n is an integer from 2 to 5; and
R1 is selected from:
wherein n=1 to 100, and wherein the modified nucleotide is incorporated by DNA polymerase in replication of a DNA template during DNA sequencing. In various embodiments, the modified dNTP may comprise a tetra-phosphate or a hexa-phosphate moiety instead of the natural triphosphate moiety.
In various aspects, the modified nucleotide is compound [16] wherein Y is O, Nuc is cytosine, n is 3, and R1 is the substituent:
In other aspects, the modified nucleotide is compound [16] wherein Y is O, Nuc is cytosine, n is 3, and R1 is the substituent:
In certain aspects, the modified nucleotide is compound [16] wherein Y is O, Nuc is cytosine, n is 3, and R1 is the substituent:
In other embodiments, the modified nucleotide is compound [16] wherein Y is O, Nuc is cytosine, n is 3, and R1 is the substituent:
In various examples, the modified nucleotide is compound [16] wherein Y is O, Nuc is cytosine. n is 3, and R1 is the substituent:
In other aspects, the modified nucleotide is compound [16] wherein Y is O, Nuc is cytosine, n is 5, and R1 is the substituent:
In various embodiments, the modified nucleotide is compound [16] wherein Y is O, Nuc is cytosine, n is 5, and R1 is the substituent:
In some examples, the modified nucleotide is compound [16] wherein Y is O, Nuc is cytosine, n is 5, and R1 is the substituent:
In various aspects, the modified nucleotide is compound [16] wherein Y is O, Nuc is cytosine, n is 5, and R1 is the substituent:
In some examples, the modified nucleotide is compound [16] wherein Y is O, Nuc is cytosine, n is 5, and R1 is the substituent:
In various embodiments, the modified nucleotide is compound [16] wherein Y is O, Nuc is cytosine, n is 5, and R1 is the substituent:
In other aspects, the modified nucleotide is compound [16] wherein Y is O, Nuc is adenosine, n is 3, and R1 is the substituent:
In certain embodiments, the modified nucleotide is compound [16] wherein Y is O, Nuc is cytosine, n is 3, and R1 is the substituent:
In various embodiments, the modified nucleotide is compound [16] wherein Y is O, Nuc is adenosine, n is 3, and R1 is the substituent:
wherein n=1 to 100.
In certain aspects, the modified nucleotide is compound [16] wherein Y is O, Nuc is adenosine, n is 3, and R1 is the substituent:
In various embodiments of the present disclosure, a modified nucleotide (modified dNTP) is described. The modified nucleotide structure is represented by compound [18],
wherein:
Nuc is a DNA base selected from A, T, C, and G;
Y is selected from OH, SH, or BH3;
n is an integer from 2 to 5;
R3 is selected from H or halogen;
R1 is selected from H, linear or branched C1-C5 alkyl, C3-C8 cycloalkyl, or aryl, optionally substituted with halogen, Me or OMe, or —(CH2CH2O)xMe wherein x is an integer 1 to 20;
L2 is selected from —(CH2)q— wherein q is an integer from 1 to 10, —CH2CH2(OCH2CH2)y— (wherein y is an integer from 1 to about 8), —(CH2)q—O—(CH2CH2O)y—CH2— (wherein q is an integer from 1 to about 10 and y is an integer from 1 to about 8), —CO(CH2)r— wherein r is an integer from 1 to about 10), —COCH2CH2(OCH2CH2)z— wherein z is an integer from 1 to 6, —COCH2CH2CONH(CH2)m— wherein m is an integer from 1 to 6, —COCH2CH2CONH(CH2CH2O)pCH2CH2— wherein p is an integer from 1 to 6, 1,4-benzenediyl, 1,3-benzenediyl, or 1,2-benzenediyl, with carbon atoms optionally and independently substituted with halogen, Me, Et, OH, OMe, or CF3, or is,
and
R4 and R5 are independently selected from H, phenyl,
wherein n=1 to 100.
In various aspects, the modified nucleotide is compound [18] wherein: Nuc is A, T, G, or C; Y is OH; n=3 or 5; R1 is H; R3 is H; L2 is the bivalent linker —(CH2)4—O—(CH2CH2O)8—CH2—, and R4 is selected from phenyl,
In various embodiments of the present disclosure, a method of enhancing an electrical signal generated from a biosensor is described. The method comprises: (a) providing a biosensor comprising source and drain electrodes and a polymerase bonded to a bridge molecule bridging the electrodes to complete an electrical circuit; (b) placing a nucleotide template to be sequenced in communication with the polymerase; (c) placing a modified dNTP in communication with the polymerase; and (d) transcribing the nucleotide template by the polymerase, wherein transcribing comprises incorporating the modified dNTP by the polymerase, and wherein incorporating the modified dNTP results in an enhanced electrical signal compared to incorporating the corresponding non-modified dNTP. In some instances, the enhanced signaling comprises at least one of a larger current spike, a distinguishing current v. time peak shape, or improved signal-to-noise ratio.
In certain examples, the modified dNTP may comprise any one of the modified nucleotides disclosed herein. Further, the enhanced electrical signal made possible by the modified dNTP distinguishes between A, G, C, and T in the nucleotide template, making sequencing of the nucleotide template more reliable. In other examples, the enhanced electrical signal is unique for incorporation of each of a modified dATP, a modified dGTP, a modified dTTP, and a modified dCTP.
In various embodiments of the present disclosure, a method of transcribing a nucleotide template is described. The method comprises: (a) providing a polymerase capable of transcribing the nucleotide template; (b) placing the nucleotide template in communication with the polymerase; (c) placing modified dNTPs in communication with the polymerase; and (d) transcribing the nucleotide template with the polymerase by incorporating the modified dNTPs, wherein the modified dNTPs comprise any one of the modified nucleotides disclosed herein.
In various embodiments of the present disclosure, signaling performance of a polymerase-based molecular electronic sensor is enhanced by the use of modified dNTPs carried in a test solution analyzed by the sensor. Many such dNTP modifications are tolerated by a polymerase in a sensor. In certain aspects, signal enhancements provided by modified dNTPs can occur through a variety of mechanisms, as discussed herein, and these mechanisms can be used as a template for rational design of such modifications.
In various embodiments, a molecular sensor usable for DNA sequencing comprises a polymerase enzyme to functionalize the sensor. The sensor also comprises a conducting bridge molecule (also referred to as a “molecular wire”). In some aspects, a conducting bridge molecule may be on the order of about 10 nm in length. The conducting bridge molecule “wires” the conjugated polymerase into a circuit comprising source and drain electrodes and the molecular wire (a molecule) bridging the electrode pair. Such a molecular wire may comprise a DNA oligonucleotide (“oligo”), protein alpha helix bridge, or other biomolecule that connects source and drain electrodes. In certain aspects, a polymerase enzyme coupled to a molecular wire element completes a current measuring circuit in the sensor. Measurement of current versus time as the polymerase incorporates nucleotides produces a signal trace that indicates the incorporation events as discrete signal spikes, (e.g., current spikes in a trace of current versus time), and discriminates and identifies the different bases being incorporated via the detailed shape and/or size of these spikes. The resulting signal is processed to determine the sequence of the template.
The critical enzyme activity monitored by such a molecular sensor is the incorporation of the various deoxynucleotide tri-phosphates (or “dNTPs”). A subject of this disclosure is, in general, an alteration of this process in order to enhance the resulting signals, which consequently improves the ability of a molecular sensor based on polymerase to determine a DNA sequence.
dNTPs
The four specific forms of dNTPs correspond to the four bases/letters of DNA, which are dATP (adenosine), dCTP (cytidine), dGTP (guanosine) and dTTP (thymidine), which differ only in the base composition. Herein, the base on a molecule may be denoted by a letter (A, C, G, T) or in general, by “Nu” or “Nuc.” All of the natural dNTPs have a triphosphate moiety, and the three phosphate groups are indicated as α, β, and γ, beginning with the phosphate attached to the 5′ OH of the deoxyribose. In a DNA chain extension that is catalyzed by polymerase, the 3′ OH group on the deoxyribose and the 5′ α-phosphate site participate in an incorporation and chain extension. The four specific dNTPs are the chemical substrates that DNA polymerase incorporates into a growing strand, guided by a template strand. The most critical feature of this process is that the β- and γ-phosphate groups are released together as a pyrophosphate group by the action of the polymerase enzyme, when the 3′ OH group of the elongating strand is coupled to the 5′ carbon-α-phosphate group of the incoming nucleotide.
The extent to which natural dNTPs can be chemically modified yet still be recognized and incorporated by a polymerase enzyme during polymerase chain reaction (PCR) remains largely unknown. In general, modifications to the 5′ carbon/α-phosphate or 3′ OH group are very limited, since these sites engage in critical coupling reactions in forming the chain. All other sites on the dNTP typically allow some degree of chemical modification. This may or may not result in native form DNA being produced, depending on whether the modifications reside on the β- and/or γ-phosphate groups released from the dNTP by the polymerase during incorporation, or elsewhere on the base, deoxyribose group or the α-phosphate that are retained in the growing strand. Specific examples include a tolerated dNTP having a large dye-label group attached to the base (see Waggoner, et al, Nucl. Acids Res. (1994) 22 (16): 3418-3422.). This modification is retained in the resulting DNA product. A specific example of modification to the γ-phosphate, in which linker and dye molecules can be attached without inhibiting the polymerase, is found in Fuller, et al, Nucleosides, Nucleotides, and Nucleic Acids, 24 (5-7):401-408, (2005). These modifications are not retained in the resulting DNA product. In general, the incorporation of dye-labeled dNTPs has been the basis of many methods of analyzing DNA using optical reporter strategies.
Disclosed herein are broad classes of dNTP modifications. These modifications are generally to the β- and/or γ-phosphate such that the modifications are not retained in the DNA synthesized by the polymerase from the modified dNTPs, although some modifications herein are also to the α-phosphate group and are retained in the synthesized DNA. In various embodiments, these forms may comprise a linker such as from the γ-phosphate to a signaling group. The signaling group may comprise a group that is charged (e.g., +1, +2, or −1, −2, etc.) under the buffering conditions used for sensor operation, such that its charge impacts current flow in the sensor circuit. For example, a signaling group may comprise a sulfonate group (—SO3−, with −1 charge), or a quaternary ammonium substituent (—R3N+ with a +1 charge). Other signaling groups attached to dNTPs may comprise dyes, sugars, polycyclic aromatic substituents, or other groups. In certain aspects, a linker enables the signaling group to come into close proximity to the molecular bridge of the sensor during incorporation of the modified dNTP carrying the linker and signaling group, thereby enhancing signal impact. There may be different signaling groups for the different bases, such as to enhance base discrimination of signals. The chemical structures of modified dNTPs, their synthesis via synthetic organic chemistry methods, and their use in molecular sensors based on polymerase are detailed herein.
It has been determined that modified dNTPs are especially effective when the molecular sensor is on the order of 10 nm in size, as illustrated in
Exemplary Molecular Electronic Biosensors for DNA Sequencing
As used herein, various chemical compounds may be labeled and identified by an Arabic number, (e.g., compounds [1], [2], [3], etc.), Other compounds may be labeled and identified by a Roman numeral, (e.g., compounds [VI], [VII], [VIII], etc.). A compound labeled with an Arabic number is distinct from a compound labeled with the equivalent Roman numeral. As an example, compound [16] and compound [XVI] are different compounds.
As used herein, sequences with repeating bases may be written in shorthand notation for convenience, wherein a subscripted integer indicates the total number of a particular base immediately preceding the subscripted integer. For example, the shorthand notation A20-C3-A30-G (SEQ ID NO: 3) denotes the sequence, A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-C-C-C-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-G (SEQ ID NO: 3).
Use of Modified dNTPs for DNA Sequencing Applications
In some examples, modifications to dNTPs comprise the addition of various groups to the γ-phosphate of the molecule. The modifications may comprise chemical moieties that provide a formal charge (e.g., +1, −1, etc.), polarity (e.g., —C═O, —OH functionality), non-polar character (e.g., hydrophobicity through use of non-polar functionality like —CH2—), steric effects (e.g., large fused ring systems). These, and other, chemical moieties can interact with native features on the polymerase enzyme, with engineered features on the polymerase, with the bridge molecule, or with a molecule bonded between the polymerase and bridge molecule. In various aspects, modifications to dNTPs may extend the polyphosphate charge from −3 (in native dNTPs) to −4, −5, −6, −7, −8 or −9, for example, depending on the total number of phosphate groups. In certain embodiments, an initial modification to a dNTP may comprise addition of a click chemistry group to the end of the polyphosphate chain, which provides a reactive moiety (e.g., an alkyne group) usable to efficiently synthesize the target modified dNTP.
In various embodiments, modified dNTPs may require an appropriate buffer solution in which to be effective for signal enhancement, relative to standard buffering conditions commonly used for polymerase reactions (such as PCR, primer extension, or reverse transcription reactions, or the in vivo conditions in various biological organisms wherein these enzymes function). In particular, buffer modifications for some embodiments may include an alteration of the salt concentration used in the buffer, to either higher salt or lower salt conditions. In certain embodiments, reduction of the salt concentration by the range of 2-fold, to 10-fold, to 100-fold, to 1000-fold, 1 million fold, up to 1 billion fold may be advantageous. Advantages may be due to decreasing the salt-based screening of electrical fields in the solution, or the increase in Debye length in the solution, or also due to the decrease in electrical measurement noise from ionic conduction from such lower ion concentrations. In other examples, increase in the salt concentration by the range of 2-fold, to 10-fold, to 100-fold, to 1000-fold, 1 million fold, up to 1 billion fold may be advantageous.
In certain aspects, alterations to the sensor system in general may enhance the effect of modified dNTPs. These alterations can include, but are not limited to, optimization of the concentration of dNTPs, the nature of the buffer solution used, the applied electrode and gate voltages, and the specific type of polymerase or mutated polymerase used in the sensor. Any combination of these alterations may be used to enhance the effects made possible by modified dNTPs. For example, lowering the ion concentration of the buffer in order to extend the Debye radius of charged groups on a modified dNTP may have enhancing effect by allowing greater electrical influence of the dNTP on the molecular bridge conductor during incorporation events.
In other aspects, a buffer may have an altered concentration or composition of metal multivalent cations required for enzyme activity. For example, divalent cations are known to play critical roles in mediating the interaction between the dNTP and a polymerase. Buffer alterations related to this may include alteration of the Mg concentration, or may comprise use of concentrations of other metal multivalent cations, for example divalent cations such as Mn, Fe, Ni, Zn, Co, Ca, Cd, Ba, Sr, Cu, or Cr. The addition of detergents or dispersing agents in the buffer may be important for some embodiments, to reduce or prevent aggregation of modified dNTPs, or reduce or prevent their aggregation with other molecules in the system.
With reference now to
In various embodiments, the use of modified dNTPs in DNA sequencing with a biosensor is disclosed. In DNA or genome sequencing applications, for example, a bridge molecule, such as a DNA oligonucleotide, is conjugated to a polymerase, the polymerase is bound with a primed single-stranded template DNA, and the electronic biosensor is provided with a buffer containing dNTPs (deoxynucleotide triphosphates) for incorporation. Electric current through the bridge molecule is monitored as the various dNTPs are incorporated by the polymerase in synthesizing the complementary strand of the template DNA. In various embodiments, native or “standard” dNTPs are used, including dATP, dCTP, dGTP, and dTTP. However, in other aspects, any or all of these standard dNTPs may be replaced by a corresponding modified dNTP.
Non-limiting examples of dNTP modifications in accordance to the present disclosure are shown in
For example,
Additional examples of modified dNTPs usable to enhance signals from a biosensor comprising a polymerase enzyme are set forth in
The modified dCTP depicted in
The modified dCTP depicted in
Further, the modified dCTP depicted in
One benefit of using modified dNTPs, (such as those illustrated in
Specific experiments using representative modified dNTPs with the molecular electronic sequencing sensor of
In various embodiments of the present disclosure, the use of chemically modified dNTPs enhance the electrical signal parameters of a molecular electronic sensor comprising a polymerase enzyme.
In other embodiments, modified dNTPs may only achieve beneficial or greater levels of signal enhancement in a system that also comprises the use of a particular native or mutated or chemically modified polymerase enzyme, or the use of an appropriate buffer, or the use of an appropriate bridge molecule.
In various embodiments, the pH and/or chemical makeup of a buffer in a test solution comprising a modified dNTP and provided to a sensor may influence the charge on various groups on modified dNTPs such as phosphate groups, other ionizable groups e.g., sulfonate, or amine groups that may be protonated. For example, phosphate groups on a modified dNTP may be all negatively charged or may be partially or fully protonated as —OH groups. In accordance to the present disclosure, various phosphate groups in tri-, tetra-, penta-, hexa-, etc. phosphate chains, may be shown as salts, partial salts, or with each of the phosphate groups protonated to —OH groups in the various drawing figures. The understanding is that what is depicted in a drawing figure for the charges on a polyphosphate chain is not limiting, and the various phosphate groups may be all negatively charged, partially protonated or fully protonated (resulting in all —OH groups). Further, the counterion on any negatively charged phosphate group oxygen atom is also not limited, and may be any M+ species (e.g., Li+), M2+ species (e.g., Mg2+), or any ammonium salt, (e.g., R3NH+). Similarly, sulfonic acid groups may be shown in their acid form (—SO3H), or as the deprotonated sulfonate anion (—SO3−).
In various embodiments, an appropriate combination of dNTP modification, polymerase modification, buffer modification and bridge molecule may result in desirable signal enhancement. Similarly, modified dNTPs for signal enhancement can potentially provide for additional enhancement through the use of such modified polymerases, modified buffers, or modified bridges. An additional benefit of the present disclosure is that additional signal enhancement is possible by optimization of these other major system parameters, relative to various embodiments of modified dNTPs.
(1) Through direct interaction of negative charges or positive charges on a substituent with the conducting portion of the molecular sensor. Specific embodiments are shown without limitation in
(2) Through direct π-π and hydrophobic interaction of aromatic rings, provided by one or more of the substituents, with the conducting portion of the molecular sensor. Specific embodiments are shown without limitation in
(3) Through both charge and π-π interactions, e.g., with a N-alkyl-pyridinium (positive) substituent or pyrene sulfonate (negative) substituent. Specific embodiments are shown without limitation in
(4) Through electrochemical reduction and oxidation of R1 (e.g., for reversibly oxidizable groups such as ferrocene or hydroquinone). Specific embodiments are shown without limitation in
(5) When R1 contains a conducting molecular component such as a graphene nano ribbon, a polythiophene polymer, or poly aromatic hydrocarbon ring ribbon structure, and the sensor contains two disconnected conductors (each linked to a different metal electrode), through creating and breaking a conductive link between said two conductors. Specific embodiments are shown without limitation in
(6) When R1 is a long, rigid molecule that is narrow near the phosphate end and wide at the other end, through steric interaction of the wide end with the conductor that stretches out the linker from polymerase to conductor, altering the interaction between the linker and the conductor in a manner dependent on the length of R1. In various aspects, the linker would contain multiple groups such as aromatic rings that could bind to the conductor and alter conductivity upon association or dissociation. With multiple groups on the linker, it will be possible to observe no dissociation of the groups from the conductor for a short linker, partial dissociation of some groups for an intermediate length linker, and complete dissociation of groups for a sufficiently long linker—each with a distinct electrical signal. The rigidity and wide end of R1 ensures that the conductor is contacted and pushed away from the polymerase when the molecule binds so that partial or complete dissociation of groups occurs for sufficiently long R1. Specific embodiments are shown without limitation for R1 and linkers between conductor and polymerase in
(7) Indirectly, by altering the conformational change of the polymerase during incorporation of a modified dNTP. In various embodiments, R1 may bind to a specific site on the polymerase near the dNTP or DNA binding site, or may alter the linker's interaction with the polymerase. Changes in the substituents n and Y can also affect the time dependence or kinetics of the conformational changes in the polymerase, which could amplify signals when the electrical conductivity between electrodes is sensitive to conformational changes. Specific examples of dNTP derivative structures are shown without limitation in
The various substituent selections will be further understood when specific species of modified dNTPs are presented and discussed.
In reference to the general chemical structure [16] in
Classes of Modified dNTPs
With continued reference to the chemical compound [17] in
In reference now to the general structure [18], R1 is selected from H, alkyl (e.g., linear or branched C1-C5), cycloalkyl (e.g., C3-C8), —(CH2CH2O)xMe wherein x is an integer 1 to about 20, or aryl, wherein any alkyl is branched to any degree and any alkyl, cycloalkyl or aryl substituent is optionally substituted with halogen, Me, or OMe. R3 is selected from H or halogen. Further in compound [18], Y=OH, SH, or BH3 and Nuc is a DNA base, such as unmodified A, T, C, or G. R4 and R5 in compound [18] are independently selected from H, alkyl (e.g., linear or branched C1-C20), cycloalkyl (e.g., C3-C12), aryl (including polycyclic substituents up to 10 rings), heteroaryl (including polycyclics up to 10 rings), ferrocene, oligothiophene, heteroaryl-alkyl, aryl alkyl, optionally and independently substituted with halogen, alkyl (linear or branched C1-C10), O-alkyl (linear or branched C1-C10), CF3, CHF2O, RSO2, amine, or amide. R4 and R5 also include, independently, oligosaccharides including various cyclodextrins, optionally substituted with O-alkyl (linear or branched C1-C10), O-benzyl, O-sulfate, methyl-(PEG)n (wherein n is from about 1 to about 20) or —O2C-alkyl (linear or branched C1-C8).
With continued reference to
Various embodiments of modified dNTPs based on dCTP are set forth in
A polymerase extension functional assay shows that polymerase can incorporate these and other modified dNTPs.
Template: 1 μM of single stranded template DNA, with primer annealed;
Template sequence: (70 bases, poly ACTG): 5′-CGC CGC GGA GCC AAG ACTG ACTG ACTG ACTG ACTG ACTG ACTG ACTG ACTG ACTG TTG CAT GTC CTG TGA-3′ (SEQ ID NO: 6);
Primer sequence: (15 bases): 5′-TCA CAG GAC ATG CAA-3′ (SEQ ID NO: 7)
Buffer: 10 mM Tris, 10 mM MgCl2, 50 mM NaCl;
dNTP concentrations: 2.5 mM of each nucleotide, 10 μM total dNTP concentration;
Enzyme: 5 Units of Klenow exo-;
Conditions: incubation for 30 minutes at 37° C.;
Imaging: 3.5% Agarose gel in TAE with ethidium bromide stain.
Lanes are as delineated in the numerical key below. Lane 4 shows the product from natural dNTPs. Lane 6 uses 4 modified dNTPs. Lane 7, 8, and 9 show three of the γ-phosphate modifications. Thus, all modified dNTPs tested produce DNA product. Lane 5 uses terminator nucleotides (ddNTPs) that cannot be extended, and the result is no product/no band as a negative control. Lanes 2 and 3 are also negative controls, without all reactants required for extension. Lanes 10 and 11 are further negative controls.
The key to the lanes in the polymerase activity assay is as follows:
1—100 base DNA size ladder
2—DAN ONLY (no polymerase or dNTPs)
3—DNA+Klenow polymerase ONLY (no dNTPs)
4—4 dNTPs (native forms)
5—4 ddNTPs (dideoxy terminators)
6—4 modified dNTPs
7—dC4P-DMA, other dNTPs native
8—dC4P-DBCP, other dNTPs native
9—dC4P-Cy7, other dNTPSs native
10—dC4P-DMA+Klenow polymerase only, no template DNA
11—dC4P-DMA ONLY, no polymerase
12—Low molecular weight DNA size ladder
The polymerase activity assay in
The synthesis of various embodiments are outlined in the Synthetic Organic Chemistry section below:
Synthetic Organic Chemistry
Chemical syntheses used to produce the various modified dNTPs herein are disclosed, including syntheses of the modified dNTPs shown in
Synthesis of DBCO-PEG-OH (Compound [IV])
See
To a solution of 2-(2-(2-aminoethoxy)ethoxy)ethan-1-ol (compound [I], 0.267 g, 1.789 mmol) in 2 ml anhydrous DCM at RT was added slowly a solution of DBCO-NHS (compound [II], 0.24 g, 0.596 mmol) in 2 ml anhydrous DCM. After completion of addition, the reaction solution was stirred at RT for 2 hours. HPLC indicated complete disappearance of the succinimide. The reaction was kept in the dark at −20° C. in a freezer. The next morning, the reaction solution was warmed up to RT and diluted with 3 ml DCM. Silica gel (5 g) was added, and the slurry evaporated to dryness in a rotary evaporator. The residual powder was loaded onto a ISCO loading cartridge and purified by column chromatography (12 g silica gel column, 5-20% methanol/DCM) to afford 0.2 g of DBCO-PEG-OH (compound [IV]). Yield: 77%
1H NMR (499 MHz, Chloroform-d) δ 7.65 (dd, J=7.6, 1.3 Hz, 1H), 7.53-7.42 (m, 1H), 7.42-7.17 (m, 6H), 6.41 (t, J=5.7 Hz, 1H), 5.12 (d, J=13.9 Hz, 1H), 3.75-3.49 (m, 10H), 3.44 (dddd, J=28.0, 10.0, 6.3, 4.0 Hz, 2H), 3.36-3.21 (m, 2H), 2.78 (ddd, J=16.8, 8.5, 6.2 Hz, 1H), 2.41 (ddd, J=14.8, 8.5, 6.1 Hz, 1H), 2.16 (dt, J=15.1, 6.2 Hz, 1H), 2.01-1.86 (m, 1H).
Mass: calculated for C25H28N2O5, [M]: 436.20, observed: [M+23] 459.5 in positive mass.
HPLC: 10 minutes HT-LC-MS method, retention time for product: 6.5 minutes.
Synthesis of DBCO-PEG-Monophosphate (Compound [V])
See
DBCO-PEG-OH (compound [IV], 35.8 mg, 0.082 mmol) was co-evaporated with anhydrous acetonitrile (2×1 ml) and then was dissolved in trimethylphosphate (0.42 ml). Phosphorous oxychloride (POCl3, 16 μL, 0.64 mmol) was added to this cooled and stirred solution, and the reaction mixture was stirred for 2 hours. This reaction mixture was added dropwise over 5 minutes to tributylammonium pyrophosphate (1 equiv, 0.082 mmol, 0.5M solution in anhydrous DMF) and tributylamine (76 mg, 0.41 mmol) was added and stirred for 60 minutes. 5 ml TEAB (0.1M) buffer was added to quench the reaction. Solvent was removed under vacuum and the resulting residue was kept in a refrigerator overnight. The next morning, the residue was purified by C18 ISCO column (15.5 g C18 column, 0-100% acetonitrile/0.1M TEAA in water) to yield approximately 45 mg compound [V]. Residual trimethylphosphate prevented any meaningful NMR spectrum. The compound [V] was directly used in the next step for the synthesis of compound [VIII].
HPLC: 10 minutes HT-LC-MS method, retention time for starting material DBCO-PEG-alcohol: 6.5 minute: retention time for product: a group of three peaks: 5.0 minutes, 5.2 minutes and 5.5 minutes.
Mass: calculated for C25H31N2O14P3, [M]: 676.4, observed: [M−1] 675.3 in negative mass.
Synthesis of dC-P4-Click (Compound VIII)
See
DBCO-PEG-monophosphate (compound [V], 45 mg, 0.06 mmol) was co-evaporated with anhydrous acetonitrile (2×1 ml) and then dissolved in anhydrous DMF (1.0 ml). Carbonyldiimidazole (compound [VI], 4 equiv., 38.7 mg, 0.24 mmol) was added and the reaction mixture was stirred at room temperature for 4 hours. Methanol (6 equiv., 14.7 μL) was then added and stirring was continued for 30 minutes. To the reaction mixture a solution of dCTP (bis)tributylammonium salt (70.2 mg, 0.084 mmol) in 0.5 ml DMF and MgCl2 (57 mg, 0.6 mmol) were added. The resulting mixture was stirred overnight. The next morning, HPLC indicated the shift from the less polar starting material DBCO-PEG-triphosphate to more polar reaction products. The crude product was purified by reverse phase C18 column on ISCO (15.5 g C18 column, 0-100% ACN/0.1M TEAA in HPLC grade water. There were a group of peaks eluting at around 30-40% ACN/0.1M TEAA in HPLC grade water. The first two fractions P1(f26+f27) were collected, solvent was removed, and the residue was dried under vacuum to give 9.2 mg compound [VIII]. The middle two fractions P2 (f28+f29) were collected, solvent was removed, the residue was dried under vacuum to give an additional 10.7 mg compound [VIII]. The last two fractions P3 (f30+f31) were collected, solvent was removed, and the residue was dried under high vacuum to give a further 6.5 mg compound [VIII]. By mass, the first peak is mainly d-C-P4-click, the second is a mixture of d-C-P4-click and traces of d-C-P5-click, d-C-P6-click and d-C-P7-click.
HPLC: 10 minutes HT-LC-MS method, retention time for starting material: a group of three peaks: 5.0 minutes, 5.2 minutes and 5.5 minutes. Retention time for product CP4-click: 4.8 and 4.9 minutes, two peaks.
1H NMR (500 MHz, Deuterium Oxide) δ 7.96 (t, J=8.5 Hz, 1H), 7.66 (d, J=7.4 Hz, 1H), 7.60-7.30 (m, 7H), 6.33 (t, J=6.7 Hz, 1H), 6.15 (q, J=7.8 Hz, 1H), 5.09 (d, J=14.4 Hz, 1H), 4.78 (s, 100H), 4.67-4.53 (m, 1H), 4.21 (d, J=5.0 Hz, 4H), 4.13 (d, J=7.1 Hz, 2H), 3.83 (d, J=14.4 Hz, 1H), 3.75 (q, J=7.1, 6.0 Hz, 2H), 3.69 (q, J=6.5, 5.2 Hz, 2H), 3.63-3.54 (m, 2H), 3.47 (dt, J=10.6, 5.3 Hz, 1H), 3.38 (dq, J=11.3, 5.9 Hz, 1H), 3.24-3.05 (m, 54H), 2.53 (dt, J=15.5, 5.8 Hz, 1H), 2.44-2.32 (m, 1H), 2.24 (tdq, J=20.8, 14.3, 7.0 Hz, 4H), 1.91 (d, J=1.2 Hz, 9H), 1.26 (td, J=7.4, 1.0 Hz, 82H).
Phosphorus NMR: −11.0 (m, integration 100), −22.4 (m, integration 100).
Mass Spec. M=965 negative ion: calculated for M-H: 964.6 Observed: 964.3.
Synthesis of dC-P4-Pip-DMA (Compound [X])
See
MIR96-IN-1-azide (compound [IX], 3.7 mg, 6.28 μmop and dC-P4-click (compound [VIII], 7.5 mg, 5.9 μmop were mixed in 0.3 ml of 1:1 water/acetonitrile and the reaction mixture was stirred at RT overnight. HPLC indicated disappearance of the starting material dCP4-click and the formation of some new less polar products. Crude mass indicated the formation of desired compound [X]. Solvent was removed and the residue was dried under vacuum to afford 8.6 mg crude compound [X].
HPLC: 10 minutes HT-LC-MS method, retention time for starting material dCP4-click: 4.8 and 4.9 minutes, two peaks, retention time for MIR96-azide: 9.6 minute, retention time for click adduct: 5.49 minute.
1H NMR (500 MHz, Methanol-d4) δ 8.12 (d, J=7.3 Hz, 1H), 8.01 (dot, J=8.7, 3.2 Hz, 3H), 7.60 (d, J=7.5 Hz, 1H), 7.51 (dd, J=20.4, 11.8 Hz, 4H), 7.43-7.20 (m, 2H), 7.16 (d, J=8.1 Hz, 1H), 7.02 (d, J=9.3 Hz, 1H), 6.38-6.19 (m, 1H), 6.02 (t, J=16.7 Hz, 0H), 5.85 (d, J=16.2 Hz, 0H), 4.67-4.51 (m, 1H), 4.51-4.21 (m, 3H), 4.07 (s, 2H), 3.78 (t, J=7.4 Hz, 1H), 3.73-3.32 (m, 9H), 3.27-3.07 (m, 25H), 3.09-2.70 (m, 6H), 2.66 (s, 1H), 2.33 (q, J=9.4, 8.5 Hz, 1H), 2.27-1.95 (m, 3H), 1.82-1.53 (m, 2H), 1.54-1.35 (m, 18H).
Phosphorus NMR: −10.63 (m, integration 100), −22.06 (m, integration 108).
Mass: M=1554.4 negative ion: calculated for M−1: 1553.4 is M−1, observed: 1552.8 calculated for M+Na−2H: 1575.4 Observed: 1574.8.
Synthesis of dCP4-Cy7 (Compound [XII])
See
Cy7-azide (compound [XI], 5.0 mg, 4.37 μmol) and dCP4-click (compound [VIII], 7.5 mg, 5.9 μmol) were mixed in 0.3 ml of 1:1 water/acetonitrile solution and stirred at RT overnight. HPLC indicated the disappearance of the starting material dCP4-click and the formation of some new products. There was still some excess Cy7-azide [XI] present in the reaction mixture. Crude mass indicated formation of the desired product. Solvent was removed and the residue was dried under vacuum to afford 7.3 mg of compound [XII].
HPLC: 10 minutes HT-LC-MS method, retention time for starting material dCP4-click: 4.8 and 4.9 minutes, two peaks, retention time for Cy7-azide: 4.59 minutes, retention time for click adduct: 4.48 minute.
1H NMR (500 MHz, Methanol-d4) δ 7.96-7.76 (m, 1H), 7.74 (d, J=1.7 Hz, 1H), 7.67-7.42 (m, 1H), 7.41-7.21 (m, 2H), 7.17-7.01 (m, 1H), 6.42 (d, J=14.0 Hz, 1H), 4.53 (d, J=37.3 Hz, 1H), 4.38-3.99 (m, 3H), 3.80-3.40 (m, 3H), 3.28-3.11 (m, 17H), 3.08-2.97 (m, 1H), 2.94 (t, J=6.8 Hz, 2H), 2.78 (t, J=6.4 Hz, 2H), 2.60-2.43 (m, 1H), 2.21 (p, J=7.1 Hz, 3H), 2.11-1.97 (m, 1H), 1.74 (p, J=6.8 Hz, 1H), 1.22 (t, J=4.3 Hz, 6H).
Phosphorus NMR: too little material was available to obtain a reasonable phosphorus NMR. The signals were very weak. However, the desired product was evident from the mass spectral data.
Mass: M=2021.9 Negative ion Calculated for M-6H+5Na: 2130.9 Observed: 2134 for neg. Positive ion Calculated for M-3H+5Na: 2132.9. Observed: 2136 for positive. (Note: 13C and 2H increase observed masses).
All of the HPLCs were taken with 10 minute: HT-LCMS method with ammonium acetate as the additive. Solvent: acetonitrile and water with 25 mM ammonium acetate. Method: 0-0.5 minute: 5% acetonitrile/water, 0.5-6.5 minute: 5-95% acetonitrile/water, 6.5-9 minute: 95% acetonitrile/water, 9-9.5 minute: 95%-5% acetonitrile/water, 9.5-10 minute: 5% acetonitrile/water.
Synthesis of dCP4-TPMD (Compound [XIV])
See
TMPD-azide-2HCl (compound [XIII], 2.28 mg, 8.85 μmol) and dCP4-click (compound [VIII], 7.5 mg, 5.9 μmol) were mixed in 0.38 ml of 1:1 water/acetonitrile and the reaction mixture was stirred at RT overnight. Acetonitrile was removed and the concentrated material loaded onto a 4 g C18 column directly and purified using 0-100% ACN/0.1M TEAA in water. There was a large peak was observed to elute around 32% ACN/0.1M TEAA in water. Solvent was removed from the eluent and the residue dried further under vacuum to afford 4.9 mg compound [XIV].
Synthesis of dCP4-Lactose (Compound [XVI])
See
2-Azidoethyl-β-D-lactopyranoside (compound [XV], 3.23 mg, 10.4 μmol) and dCP4-click (compound [VIII], 10 mg, 7.86 μmol) were mixed in 0.5 ml of 1:1 water/acetonitrile and the reaction mixture was stirred at RT overnight. Acetonitrile was removed and the concentrated material loaded to a 4 g C18 column directly and purified using 0-100% ACN/0.1M TEAA in water. There was a large peak observed to elute around 25% ACN/0.1M TEAA in water. Solvent was removed from the eluent and the residue dried under vacuum to afford 10.4 mg of compound [XVI]. Mass from HT lab confirms desired mass was observed. HPLC indicates the product has a different retention time from the starting material dCP4-Click [VIII].
Synthesis of dCP4-PEG9 (Compound [XVIII])
See
PEG9-azide (compound [XVII], 3.4 mg, 8 μmol) and dCP4-click (compound [VIII], 7.5 mg, 5.9 μmol) were mixed in 0.38 ml of 1:1 water/acetonitrile and the reaction mixture was stirred at RT overnight. Acetonitrile was removed and the concentrated mixture loaded to a 4 g C18 column directly and purified using 0-100% ACN/0.1M TEAA in water. A large peak was observed to elute with 33% ACN/0.1M TEAA in water. After removing solvent, and drying under vacuum for 2 hours, 5.0 mg compound [XVIII] was obtained. Mass spec confirmed the identity as compound [XVIII]. HPLC showed a different retention time from the starting material dCP4-Click [VIII].
With reference now to
Similarly in
With reference now to
In various embodiments, the bridge molecule may purposely comprise an insulating link, such as cyclohexane-1,4-diyl at the branch point that links the bridge molecule to the polymerase. R1 of
The combination of the modified dATPs of
When a modified dATP of
Additional modified dNTPs include the following compounds comprising thio or borano modifications:
As shown by the structures above, the thio and borano modification may be at the α-, β-, or γ-phosphate of the triphosphate of the dNTP. The placement of these small modifications close to the base may enhance signaling of an incorporation even involving the modified dNTP through alteration of enzyme action, or proximity of the modification to the molecular bridge, while still being very well tolerated by the enzyme. Other atomic level modifications incorporating similar numbers of bonds could also be considered beyond sulfur and boron substitution, (e.g., iodine atoms).
Affinity Groups in Modified dNTPs
Further embodiments of the present disclosure comprise the use of an affinity group in a modified dNTP with a corresponding affinity complement positioned on the sensor so as to further enhance the influence of the signaling group on the current through the molecular sensor. In various embodiments, an affinity group is provided between the polyphosphate chain and the signaling group, closer to the signaling group end of the tether. The purpose of this is arrangement is to promote the most impactful positioning of the signaling group relative to the molecular complex of the sensor, and to increase the duration of the interaction of the dNTP with the conducting bridge molecule of the sensor. An affinity complement present on the complex promotes the positioning and residence of a charge group on the modified dNTP to have larger impact on current through the bridge. In certain examples, different affinity groups may be employed on the dNTP for each base of the dNTP (C, G, A, T). The affinity group can be highly specific, such as a single stranded DNA 5-mer that would have affinity to its complementary portion of a DNA oligo used as the molecular bridge of the sensor, or it can just represent a charge affinity, such as a negative charge on the dNTP being attracted to a positive charge on the bridge molecule.
Complementary oligos of including DNA analogs may also be beneficial for this purpose, as then can provide tunable binding energies in shorter oligos. For example, such oligos may comprise RNA, PNA (peptide nucleic acid) or LNA (locked nucleic acid) in place of native DNA, or base analogues such as inosine. For the case of graphene nanoribbon bridge, a group comprising a pyrene could have affinity to the bridge via pi-pi stacking interaction of pyrene and graphene. More generally, a pyrene group attached to the bridge and a pyrene group located on the dNTP would have affinity to each other via π-π stacking. Other affinity groups could use material binding peptides, cognate to a material bound to the bridge, or interacting proteins such as two components of a protein complex, or a small molecule or peptide antigen and a cognate antibody of Fab antibody binding domain conjugated to the bridge, or aptamers. Such bindings would preferably be selected and performed under conditions of weaker binding or transient interaction, as it is not desirable to have these interactions persist for more than the timescale of seconds, and preferably only on the scale of 10's to 100's of milliseconds. One or more affinity complements could reside on the sensor complex, the same, or different for the different dNTP affinity groups. In various embodiments, DNA oligos in the 3-mer to 30-mer range suffice as selectable, specific affinity groups for modified dNTPs, as do oligos that use modified forms of DNA, or DNA analogs that hybridize to DNA.
Modified dNTPs, methods of synthesizing modified dNTPs, and the use of modified dNTPs for enhanced signaling of dNTP incorporation events during DNA sequencing in molecular sensors comprising polymerase are provided. In the detailed description herein, references to “various embodiments”, “one embodiment”, “an embodiment”, “an example embodiment”, etc., indicate that the embodiment described may include a particular feature, structure, or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it is submitted that it is within the knowledge of one skilled in the art to affect such feature, structure, or characteristic in connection with other embodiments whether or not explicitly described. After reading the description, it will be apparent to one skilled in the relevant art(s) how to implement the disclosure in alternative embodiments.
Benefits, other advantages, and solutions to problems have been described herein with regard to specific embodiments. However, the benefits, advantages, solutions to problems, and any elements that may cause any benefit, advantage, or solution to occur or become more pronounced are not to be construed as critical, required, or essential features or elements of the disclosure. The scope of the disclosure is accordingly to be limited by nothing other than the appended claims, in which reference to an element in the singular is not intended to mean “one and only one” unless explicitly so stated, but rather “one or more.” Moreover, where a phrase similar to ‘at least one of A, B, and C’ or ‘at least one of A, B, or C’ is used in the claims or specification, it is intended that the phrase be interpreted to mean that A alone may be present in an embodiment, B alone may be present in an embodiment, C alone may be present in an embodiment, or that any combination of the elements A, B and C may be present in a single embodiment; for example, A and B, A and C, B and C, or A and B and C.
All structural, chemical, and functional equivalents to the elements of the above-described various embodiments that are known to those of ordinary skill in the art are expressly incorporated herein by reference and are intended to be encompassed by the present claims. Moreover, it is not necessary for a molecule, composition, or use to address each and every problem sought to be solved by the present disclosure, for it to be encompassed by the present claims. Furthermore, no chemical, component, or use in the present disclosure is intended to be dedicated to the public regardless of whether the chemical, component, or use is explicitly recited in the claims. No claim element is intended to invoke 35 U.S.C. 112(f) unless the element is expressly recited using the phrase “means for.” As used herein, the terms “comprises”, “comprising”, or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a chemical, chemical composition, process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such chemical, chemical composition, process, method, article, or apparatus.
This application claims priority to U.S. Provisional Pat. App. Ser. No. 62/369,696, filed Aug. 1, 2016, entitled “Modified Nucleotides for Molecular Sensors,” and U.S. Provisional Pat. App. Ser. No. 62/452,466, filed Jan. 31, 2017, entitled “Modified Nucleotide Triphosphates for Molecular Electronic Sensors,” the disclosures of which are incorporated herein by reference in their entireties.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2017/044965 | 8/1/2017 | WO | 00 |
Number | Date | Country | |
---|---|---|---|
62452466 | Jan 2017 | US | |
62369696 | Aug 2016 | US |